Annette Bley

Dr. Annette Bley


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CKChristiane Kehrer
Christiane Kehrer
SGSamuel Groeschel
Samuel Groeschel
BKBirgit Kustermann-Kuhn
Birgit Kustermann-Kuhn
FBFriederike Bürger
Friederike Bürger
WKWolfgang Köhler
Wolfgang Köhler
OLOn Behalf Of The German Leukonet
On Behalf Of The German Leukonet
Metachromatic leukodystrophy (MLD) is a rare, genetic neurodegenerative disease. It leads to progressive demyelination resulting in regression of development and early death. With regard to experimental therapies, knowledge of the natural course of the disease is highly important. We aimed to analyse onset and character of first symptoms in MLD and to provide detailed natural course data concerning language and cognition.

3 May 2024 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
CPChristian Posern
Christian Posern
BDBenjamin Dreyer
Benjamin Dreyer
SMSarah L. Maier
Sarah L. Maier
FEFlorian Eichler
Florian Eichler
Michael GelbMichael Gelb
Michael Gelb
SMSimona Murko
Simona Murko
Canavan disease is a devastating neurometabolic disorder caused by accumulation of N acetylaspartate in brain and body fluids due to genetic defects in the aspartoacylase gene (ASPA). New gene therapies are on the horizon but will require early presymptomatic diagnosis to be fully effective. We therefore developed a fast and highly sensitive liquid chromatography mass spectrometry (LC-MS/MS)-based method for quantification of N-acetylaspartate in dried blood spots and established reference ranges for neonates and older controls. With this test, we investigated 45 samples of 25 Canavan patients including 8 with a neonatal sample. Measuring N-acetylaspartate concentration in dried blood with this novel test, all Canavan patients (with variable severity) were well separated from the control group (median; range: 5.7; 1.6-13.6 μmol/L [n = 45] vs 0.44; 0.24-0.99 μmol/L [n = 59] (p < 0.05)). There was also no overlap when comparing neonatal samples of Canavan patients (7.3; 5.1-9.9 μmol/L [n = 8]) and neonatal controls (0.93; 0.4-1.8 μmol/L [n = 784]) (p < 0.05). We have developed a new LC-MS/MS-based screening test for early postnatal diagnosis of Canavan disease that should be further evaluated in a population-based study once a promising treatment becomes available. The method meets the general requirements of newborn screening and should be appropriate for multiplexing with other screening approaches that combine chromatographic and mass spectrometry techniques.